H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biolinerx (BLRX – Research Report) today and set a price target of $19.00. The company’s shares closed last Tuesday at $2.01, close to its 52-week low of $1.93.
According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -13.7% and a 24.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Biolinerx.
Biolinerx’s market cap is currently $97.5M and has a P/E ratio of -1.73.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLineRx Ltd. is a clinical-stage biopharmaceutical company, which includes indentifying, in-licensing, and developing therapeutic candidates. Its in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical and clinical stages, and then partners with pharmaceutical companies clinical development and commercialization. The company was founded in April 2003 and is headquartered in Modi’in, Israel.
Read More on BLRX:
- Morgan Stanley Sticks to Its Hold Rating for Citigroup (C)
- Kinross Gold (KGC) Received its Third Buy in a Row
- Honest Company (HNST) Gets a Hold Rating from Morgan Stanley
- Bank of America Securities Reaffirms Their Sell Rating on Plains All American (PAA)
- Bank of America Securities Keeps Their Sell Rating on Plains GP Holdings (PAGP)